

Immune Monitoring Study for Patients with Glioblastoma or Gliosarcoma

A study for **adults** with glioblastomas or gliosarcomas.



+ Objective

National Cancer Institute (NCI) researchers are conducting a study of people with glioblastoma and gliosarcoma tumors.

This study will determine if immune checkpoint inhibitors results in an immune response in the blood and if this response can shrink and control the cancer cells in the brain.

What the study involves:

- Must be able to start within 5 weeks of completion of initial chemoradiation
- Physical and neurological examination
- EKG to evaluate the heart
- Patient questionnaire about health and symptoms
- MRIs and neurological function tests
- Study of tumor tissue from prior surgeries
- Your samples used for a health evaluation
- Blood draws to evaluate the immune response
- Receive one oral drug and two IV drugs during the study:
 - Temozolimide orally 5 days per month for 16 cycles
 - Nivolumab IV days 1/15 for the first 4 cycles then once per cycle for the remaining 12 cycles (total 16 cycles)
 - Ipilimumab IV once per cycle for 4 cycles
 - One cycle equals 28 days

You can participate if you:

- Are age 18 or older
- Are diagnosed with a glioblastoma or gliosarcoma
- Have had a complete resection and chemoradiation
- Have normal organ function
- Have no prior immunotherapy or investigational treatments
- Are not taking steroid treatments

You can participate in this study by visiting the NIH at Bethesda, Maryland for a clinical assessment.

Questions?

Contact us at **(240) 760-6010** or
NCINOBReferrals@mail.nih.gov

clinicaltrials.gov ID: NCT04817254

